FHTX logo

FHTX
Foghorn Therapeutics Inc

624
Mkt Cap
$269.43M
Volume
160,868.00
52W High
$6.95
52W Low
$3.26
PE Ratio
-3.77
FHTX Fundamentals
Price
$4.59
Prev Close
$4.79
Open
$4.78
50D MA
$5.30
Beta
1.84
Avg. Volume
191,945.81
EPS (Annual)
-$1.18
P/B
-2.40
Rev/Employee
$291,594.34
$221.22
Loading...
Loading...
News
all
press releases
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have earned an average rating of "Moderate Buy" from the ten ratings firms that are currently covering the firm, Marketbeat...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·12d ago
News Placeholder
What is HC Wainwright's Forecast for FHTX FY2026 Earnings?
Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Foghorn Therapeutics in a report released on Thursday, March 12th. HC...
MarketBeat·28d ago
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Downgraded to Hold Rating by Wall Street Zen
Wall Street Zen cut Foghorn Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat·1mo ago
News Placeholder
Brokers Offer Predictions for FHTX FY2030 Earnings
Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Foghorn Therapeutics in a research report issued to...
MarketBeat·1mo ago
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Earns "Outperform" Rating from Wedbush
Wedbush reiterated an "outperform" rating and issued a $10.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday...
MarketBeat·1mo ago
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -19.72% and +14.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of...
MarketBeat·1mo ago
News Placeholder
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (NASDAQ:FHTX)
HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Foghorn Therapeutics in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of -2.04% and +0.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
<
1
2
...
>

Latest FHTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.